pancreatic-ductal-adenocarcinoma

Documents about pancreatic-ductal-adenocarcinoma

• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors#901841ClinicalTrials.gov
• Toward understanding the contribution of tumor-induced neoneurogenesis to human pancreatic ductal adenocarcinoma progression#344524HAL (France)
• Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy#825279ClinicalTrials.gov
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.#880737ClinicalTrials.gov
• Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel#394672ClinicalTrials.gov
• Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors#833361ClinicalTrials.gov
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)#268024ClinicalTrials.gov
• Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers#904478ClinicalTrials.gov
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors#1009508ClinicalTrials.gov
• Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors#812228ClinicalTrials.gov
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications#826631ClinicalTrials.gov
• [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications#855742ClinicalTrials.gov
• Supplementary file 1_Targeting cancer matrix mechanics: fibronectin fiber relaxation correlates with ADAM8 expression in PDAC and is amenable to in vitro modulation.pdf#430025Figshare
• The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma#634722eScholarship
• GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors#889624ClinicalTrials.gov
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation#843941ClinicalTrials.gov
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors#158233ClinicalTrials.gov
• Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis#439911Springer Nature OA
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies#813349ClinicalTrials.gov
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors#884251ClinicalTrials.gov
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.#373613ClinicalTrials.gov
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors#876209ClinicalTrials.gov
• A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification#805511ClinicalTrials.gov
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies#803666ClinicalTrials.gov
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9#888748ClinicalTrials.gov
• Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus).#1031793ClinicalTrials.gov
• Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor#912606ClinicalTrials.gov
• A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010#802106ClinicalTrials.gov
• A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.#886504ClinicalTrials.gov
• FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)#882957ClinicalTrials.gov
• A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)#802132ClinicalTrials.gov